Akero Therapeutics, Inc. financial data

Symbol
AKRO on Nasdaq
Location
601 Gateway Boulevard, Suite 350, South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 8, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.61K % -37.8%
Debt-to-equity 8.62 % +3.6%
Return On Equity -31.6 % -6.8%
Return On Assets -29.1 % -6.49%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 80M shares +15.2%
Common Stock, Shares, Outstanding 79.9M shares +15.5%
Entity Public Float 1.57B USD -37.7%
Common Stock, Value, Issued 8K USD +14.3%
Weighted Average Number of Shares Outstanding, Basic 81.7M shares +18.2%
Weighted Average Number of Shares Outstanding, Diluted 81.7M shares +18.2%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 280M USD +41.6%
General and Administrative Expense 41.1M USD +13.7%
Operating Income (Loss) -321M USD -37.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -284M USD -39.1%
Earnings Per Share, Basic -3 USD/shares -10.1%
Earnings Per Share, Diluted -3 USD/shares -10.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 220M USD -29%
Marketable Securities, Current 522M USD +16%
Cash, Cash Equivalents, and Short-term Investments 1.09B USD +28%
Assets, Current 765M USD -1.47%
Property, Plant and Equipment, Net 15K USD -25%
Operating Lease, Right-of-Use Asset 621K USD -29.8%
Other Assets, Noncurrent 108K USD -76.9%
Assets 1.11B USD +28.2%
Accounts Payable, Current 13.2M USD -9.05%
Employee-related Liabilities, Current 3.72M USD +19%
Liabilities, Current 60.4M USD +93.8%
Operating Lease, Liability, Noncurrent 372K USD -45.2%
Liabilities 83.3M USD +24.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax 988K USD
Retained Earnings (Accumulated Deficit) -967M USD -41.5%
Stockholders' Equity Attributable to Parent 1.03B USD +28.5%
Liabilities and Equity 1.11B USD +28.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -67.7M USD -92.6%
Net Cash Provided by (Used in) Financing Activities 396M USD +7.79%
Net Cash Provided by (Used in) Investing Activities -482M USD -934%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 79.9M shares +15.5%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 220M USD -29%
Interest Paid, Excluding Capitalized Interest, Operating Activities 980K USD +27.6%
Deferred Tax Assets, Valuation Allowance 242M USD +36.5%
Deferred Tax Assets, Gross 249M USD +38.5%
Operating Lease, Liability 679K USD -28.8%
Depreciation 1K USD -90.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -283M USD -38.5%
Lessee, Operating Lease, Liability, to be Paid 732K USD -31.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 208K USD -40.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 351K USD +2.93%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 53K USD -53.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 208K USD -40.7%
Deferred Tax Assets, Operating Loss Carryforwards 116M USD +31.2%
Unrecognized Tax Benefits 5.89M USD +73.6%
Lessee, Operating Lease, Liability, to be Paid, Year Four 208K USD -40.7%
Operating Lease, Payments 333K USD +2.78%
Additional Paid in Capital 1.5B USD +43.9%
Deferred Tax Assets, Net of Valuation Allowance 7.19M USD +168%
Share-based Payment Arrangement, Expense 32.5M USD +20.7%
Interest Expense 4.77M USD +19.1%